Skip to main content

Metabolic Syndrome X

Metabolic Diseases
7
Pipeline Programs
11
Companies
8
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 10 programs with unclassified modality

Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.

$70.5B marketMature↑ Growing30 products15 companies

Key Trends

  • GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
  • SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
  • Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins

Career Verdict

Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
#2OZEMPICGrowing
$9.2B
Novo Nordisk·Peak12.4yr
#3JARDIANCEGrowing
$8.8B
#5FARXIGAGrowing
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

FXa Inhibitors (Anticoagulants)
$18.3B(26%)

stable, mature franchise

GLP-1 Agonists
$18.2B(26%)

rapid growth, expanding indications

SGLT2 Inhibitors
$9.4B(13%)

growing, cardio-renal expansion

Insulin Analogs
$7.8B(11%)

stable, generics pressure

DPP-4 Inhibitors
$5.4B(8%)

declining, patent cliff 2027

Career Outlook

Growing

Metabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.

Breaking In

Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.

For Experienced Professionals

Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.

In-Demand Skills

Commercial acumen and healthcare economics (GLP-1 market dynamics)Regulatory affairs (label expansion, indication creep for SGLT2/GLP-1)Digital health and CGM/insulin device experienceReal-world evidence generation and health outcomes research

Best For

Brand Manager (peak-cycle GLP-1 products)Medical Science Liaison (cardio-renal expansion)Market Access / Health Economics (SGLT2 outcomes)Commercial Operations (launch support for next-gen)

Hiring Landscape

$153K-$274K

Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.

574
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

270Growing
154Growing
42Stable
38Stable

By Department

Commercial(29%)
$220K
Engineering(22%)
$197K
Manufacturing(8%)
$274K
Clinical Operations(4%)
$153K

Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.

On Market (1)

Approved therapies currently available

Boehringer Ingelheim
MICARDISApproved
telmisartan
Boehringer Ingelheim
Angiotensin 2 Receptor Blocker [EPC]oral1998
2M Part D

Competitive Landscape

8 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
1
fenofibratePhase 4
GW677954Phase 2
Abbott
AbbottABBOTT PARK, IL
2 programs
1
1
fenofibratePhase 41 trial
Study drugs: Metformin and fenofibratePhase 21 trial
Active Trials
NCT00400231Completed124Est. Mar 2008
NCT00304993Completed30Est. Feb 2005
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
TelmisartanPHASE_3Small Molecule
Medtronic
MedtronicNJ - Phillipsburg
1 program
1
TelmisartanPhase 3Small Molecule1 trial
Active Trials
NCT00147264Completed120Est. Nov 2006
Prevail Therapeutics
1 program
1
LY518674Phase 21 trial
Active Trials
NCT00327002Completed40Est. Nov 2006
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
Environmental Triggers Of Cardiometabolic DiseaseN/A1 trial
Metabolic Syndrome and Related Diseases in Healthcare WorkersN/A1 trial
Active Trials
NCT01548300Completed66Est. Dec 2014
NCT06543706Completed7,432Est. Nov 2023
GSK
GSKLONDON, United Kingdom
2 programs
GW677954PHASE_21 trial
fenofibratePHASE_4
Active Trials
NCT00264667Completed290Est. Jun 2007
Linnaeus Therapeutics
Linnaeus TherapeuticsNJ - Haddonfield
1 program
Egg interventionN/A1 trial
Active Trials
NCT06660251Completed33Est. May 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Abbottfenofibrate
MedtronicTelmisartan
Prevail TherapeuticsLY518674
GSKGW677954
AbbottStudy drugs: Metformin and fenofibrate
UNION therapeuticsMetabolic Syndrome and Related Diseases in Healthcare Workers
Linnaeus TherapeuticsEgg intervention
UNION therapeuticsEnvironmental Triggers Of Cardiometabolic Disease

Clinical Trials (8)

Total enrollment: 8,135 patients across 8 trials

Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia

Start: Jan 2001Est. completion: Feb 200530 patients
Phase 4Completed

Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial

Start: Apr 2004Est. completion: Nov 2006120 patients
Phase 3Completed

A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism

Start: Jan 2006Est. completion: Nov 200640 patients
Phase 2Completed

Study In Patients With Dyslipidaemia

Start: Dec 2005Est. completion: Jun 2007290 patients
Phase 2Completed
NCT00400231AbbottStudy drugs: Metformin and fenofibrate

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

Start: Aug 2005Est. completion: Mar 2008124 patients
Phase 2Completed
NCT06543706UNION therapeuticsMetabolic Syndrome and Related Diseases in Healthcare Workers

Metabolic Syndrome and Related Diseases in Healthcare Workers

Start: Nov 2022Est. completion: Nov 20237,432 patients
N/ACompleted

Effect of Meat and Egg on TMAO in Plasma and Urine in Subjects with and Metabolic Subjects

Start: Feb 2020Est. completion: May 202433 patients
N/ACompleted
NCT01548300UNION therapeuticsEnvironmental Triggers Of Cardiometabolic Disease

Environmental Triggers Of Cardiometabolic Disease

Start: Feb 2011Est. completion: Dec 201466 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.